INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024.Dr. Runge has served on Lilly's board since 2013, including as a member of the board's Science and Technology Committee and Ethics and Compliance Committee. He is currently the CEO of Michigan Medicine, executive vice president for medical affairs at the University of Michi ...

Eli Lilly (LLY) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this drugmaker, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

With the current market volatility, knowing which biotech stocks to buy on the dip can lead to lucrative returns as the industry is likely to recover faster than the market average. After all, many of the most prominent biomedical developers see their stock price rise or fall based on their drug success.That’s because no matter the market conditions, the critical medicines produced by biotech companies remain in demand by the patient populations that rely on them. For example, the price of insulin, no matte ...

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.Good afternoon! Novo Nordisk and Eli Lilly have so far dominated the booming market for a class of weight loss and diabetes drugs. But Eli Lilly may be starting to gain an edge over its Danish competitor in the two-horse race to capitalize on the soaring demand for those treatments, also known as GLP-1s. That became clear last week after the pair reported their respective second-quarter earnings. "Lilly is pu ...

KKStock I have written several articles regarding the Glp-1 drugs, which I forecast to become the largest-selling pharmaceutical class ever, with 2030 US sales of $150 billion. The benefits of these drugs extend to lessening the chronic diseases associated with obesity that are responsible for significant healthcare spending. These include Type 2 diabetes, cardiovascular disease, obstructive sleep apnea, liver fibrosis, knee osteoarthritis, kidney disease, and possibly several CNS diseases. In fact, Novo No ...

Eli Lilly and Company’s (LLY) second-quarter 2024 results were exceptionally strong, beating estimates for earnings and sales.Moreover, adjusted earnings per share of $3.92 rose 86% year over year. Revenues of $11.3 billion rose 36% year over year.Strong demand for its successful GLP-1-based treatments, Mounjaro and Zepbound, and other key drugs, Verzenio and Taltz, pulled up the top line in the quarter. Almost all key drugs, Mounjaro, Zepbound, Taltz and Verzenio, beat expectations. Mounjaro and Zepbound t ...

How much upside could this juggernaut stock possibly have left?With shares of Eli Lilly (LLY 2.68%) temporarily jumping more than 10% on Aug. 8 following its earnings report for the second quarter, it's easy to conclude that the company's spate of good performance is destined to continue forever.But is there evidence to actually support that assertion, or is it a mirage masking an investment that's sure to burn investors who buy in right now? There's at least one argument in favor of each of those perspecti ...

Eli Lilly (LLY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a c ...

The second-quarter earnings season has come to an end for large drug and biotech companies, with Eli Lilly (LLY) reporting its results last week. Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.As of Aug 7, the Earnings Trends report showed that 85.7% of medical companies beat estimates for earnings and 75.5% beat the same for revenues. While earnings per share (EPS) rose 17.1% year over year ...